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 INTRODUCTION 
 Prion diseases (transmissible spongiform encephalopathies) are 
subacute neurodegenerative diseases that affect both humans 
and animals. Many prion diseases, including natural sheep 
scrapie, bovine spongiform encephalopathy, chronic wasting 
disease in cervids, and variant Creutzfeldt – Jakob disease in 
humans, are acquired peripherally such as by oral exposure. 
After exposure, prions first replicate upon follicular dendritic 
cells (FDC) as they make their journey from the site of infec-
tion to the central nervous system (a process termed neuro-
invasion). 1 – 5 FDC are a unique subset of stromal cells resident 
within primary B-cell follicles and germinal centers of lym-
phoid tissues. 6 Prion accumulation and replication upon FDC 
is critical for efficient disease pathogenesis as in their absence, 
neuroinvasion is impaired. 1 – 3,7 During prion disease aggrega-
tions of PrP Sc , an abnormally folded isoform of the cellular prion 
protein (PrP C ) accumulate in affected tissues. Prion infectiv-
ity co-purifies with PrP Sc and is considered to constitute the 
major, if not sole, component of the infectious agent. 8,9 Host 
cells must express cellular PrP C to sustain prion infection, and 
FDC express high levels of PrP C on their surfaces. 7,10,11 From 
lymphoid tissues, prions appear to invade the central nervous 
system via the peripheral nervous system 12 although hematog-
enous spread cannot be entirely excluded. 
 Gut-associated lymphoid tissue (GALT) comprises chiefly of 
the appendix, tonsils, Peyer ’ s patches, colonic and cecal patches, 
and isolated lymphoid follicles. Together with the mesenteric 
lymph nodes (MLNs), these tissues help protect the host from 
gastrointestinal infections. However, our studies in mice show 
that after oral exposure early prion replication upon FDC in 
Peyer ’ s patches is obligatory for efficient neuroinvasion. 3 For 
prions to replicate on FDC in Peyer ’ s patches after ingestion of 
a contaminated meal they must first cross the follicle-associated 
epithelium (FAE), but the mechanism by which this occurs is 
uncertain. The uptake of prions by several cell types includ-
ing microfold cells (M cells), enterocytes, and mononuclear 
phagocytes has been proposed, but definitive confirmation of a 
specific uptake mechanism  in vivo is lacking. The identification 
of the cells and molecules involved in the trans-epithelial trans-
port of prions may identify important processes that influence 
disease susceptibility and to which intervention strategies can 
be developed. 
 The luminal surface of the intestine limits the access of 
pathogenic microorganisms to the underlying host tissues, and 
is protected by a single layer of epithelial cells bound by tight 
junctions. Located within the FAE of Peyer ’ s patches and occa-
sionally within villus epithelia are M cells, a unique subset of 
epithelial cells specialized for the transepithelial transport of 
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macromolecules and particulate antigens. 13,14 M cells enable 
the host ’ s immune system to sample the intestinal lumen and 
mount an appropriate immune response. However, some patho-
genic microorganisms exploit M cells and use them to gain 
entry into mucosal tissues. 15 Data from the immunohistologi-
cal tracing of prion-infected brain homogenate 16,17 or  in vitro 
studies of Caco-2 cells 18 suggest that M cells are also plausible 
sites for the transcytosis of prions across the intestinal epithe-
lium. However, similar studies suggest that this translocation 
occurs via enterocytes independently of M cells. 19,20 In response 
to inflammatory stimuli, mononuclear phagocytes within the 
lamina propria including macrophages and classical dendritic 
cell (DC) (a distinct population from stromal FDC 6 ) can insert 
dendrites through the tight junctions between enterocytes. These 
projections enable mononuclear phagocytes to directly sample 
the luminal contents. 21,22 As our own data show that the tem-
porary depletion of CD11c   +   mononuclear phagocytes impairs 
oral prion pathogenesis, 23 these data highlight another potential 
route which may influence the transepithelial transport of prions 
during inflammatory conditions in the intestine. Thus, although 
several cell populations are plausible sites of prion transcytosis 
across the FAE into Peyer ’ s patches, definitive evidence of their 
role  in vivo is lacking. 
 The tumor necrosis factor (TNF) superfamily member 
receptor activator of NF-  B ligand (RANKL) is selectively 
expressed by subepithelial stromal cells beneath the FAE in 
Peyer ’ s patches. 13 RANKL signals via its receptor RANK (recep-
tor activator of NF-  B), which is expressed by epithelial cells 
throughout the intestine. RANKL is the critical factor that con-
trols the differentiation of RANK-expressing enterocytes into 
M cells. 13 Furthermore, M cells are depleted  in vivo by RANKL 
neutralization, and are absent in RANK-deficient mice. Data 
from histological studies suggest M cells acquire prions after 
oral exposure. 16,17 Here, to determine the influence of M cells 
in prion uptake from the gut lumen, M cells were depleted in 
mice by treatment with an anti-RANKL monoclonal antibody 
(mAb) and the effects on oral prion pathogenesis studied. Our 
data show that following RANKL neutralization, both the early 
prion accumulation upon FDC in Peyer ’ s patches and neuro-
invasion were blocked. Together, these data suggest that M cells 
are important sites of prion uptake from the gut lumen into 
Peyer ’ s patches. 
 RESULTS 
 Depletion of M cells in the FAE of Peyer ’ s patches by 
RANKL neutralization 
 To study the requirement for M cells in the transcytosis of pri-
ons across the FAE i n vivo , RANKL neutralization was used to 
transiently deplete these cells before oral prion exposure. 13 Mice 
were injected intraperitoneally with the IK22-5 rat anti-mouse 
RANKL-specific mAb every 2 days for 8 days as described 13 and 
tissues collected 24  h after the last treatment. A parallel group 
of mice were treated with an isotype-matched nonspecific rat 
IgG2a   mAb as a control (control Ig). Glycoprotein 2 (GP2) is 
a novel, specific surface marker for M cells. 24,25 As anticipated, 
the number of GP2   +   M cells in the FAE of Peyer ’ s patches of 
anti-RANKL mAb-treated mice was dramatically and sig-
nificantly reduced when compared with controls ( Figure 1 ; 
 P  <  0.0079). In contrast, RANKL neutralization did not signifi-
cantly affect the number of GP2   −   UEA-1   +   goblet cells ( Figure 1 ; 
 P  =  0.241). 
 RANKL neutralization does not affect FDC status 
 As prion replication upon PrP C -expressing FDC within the 
GALT is important for efficient neuroinvasion from the intes-
tine, 1,3 we next determined the effect of RANKL neutralization 
on FDC status. FDC in mice characteristically express high lev-
els of complement receptors 1 (CR1 / CD35) and 2 (CR2 / CD21) 26 
and cellular PrP C . 7,10,11 Immunohistochemical (IHC) analysis 
suggested there was no observable difference in the status of 
CD21 / CD35-expressing FDC within B-cell follicles in the 
GALT and spleens of control Ig and anti-RANKL mAb-treated 
mice ( Figure 2a ). The expression of PrP C by FDC was likewise 
unaffected by these treatments ( Figure 2b ). These data are 
consistent with the expression of negligible levels of  Tnfrsf11a 
(which encodes RANK) by FDC ( Supplementary Figure 1 
online). Meta-analysis of mRNA micro-array data from a large 
collection of data sets ( n  =  136 individual samples) represent-
ing different mouse cells and tissues showed high expression of 
 Tnfrsf11a by Peyer ’ s patch FAE, osteoclasts, and lymphoid tissue 
inducer cells, but negligible levels by FDC. An important role 
for RANKL – RANK signaling in osteoclast function has been 
described. 27 However, no observable effects of RANKL neutrali-
zation on the presence and distribution of F4 / 80   +   and CD11c   +  
mononuclear phagocytes within the intestine, GALT, and spleen 
were observed ( Figure 2c ). These data are consistent with the 
expression of negligible levels of  Tnfrsf11a by tissue macrophages 
and classical DC from Peyer ’ s patches, lymph nodes, and spleen 
( Supplementary Figure 1 online). Furthermore, the density and 
distribution of CD11c   +   cells was not affected within crypto-
patches of RANKL   −  /  −   mice. 28 Together, these data confirm 
that RANKL neutralization depletes M cells within the FAE 
without apparent influence on the status of FDC or mononuclear 
phagocytes in the intestine. 
 M cell-depletion blocks the early accumulation of prions 
upon FDC in Peyer ’ s patches 
 Within weeks after oral exposure, ME7 scrapie prions accumu-
late first upon FDC within the Peyer ’ s patches where they persist 
at high levels until the terminal stages of disease. 1,3,23 Therefore, 
we next determined the effect of M cell-depletion on the uptake 
of prions into Peyer ’ s patches. Mice were treated for 8 days with 
anti-RANKL mAb to deplete their M cells. A separate group of 
mice was treated with control Ig. Two days after the last antibody 
injection, when M cells were significantly depleted in the FAE 
by RANKL neutralization, mice were orally exposed to ME7 
scrapie prions. 
 In this study, the normal cellular form of the prion protein is 
referred to as PrP C and two distinct terms (PrP Sc and PrP d ) are 
used to describe the disease-specific, abnormal accumulations 
of PrP that are characteristically found only in prion-affected 
tissues. Prion disease-specific PrP accumulations are relatively 
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resistant to proteinase K (PK) digestion, whereas cellular PrP C 
is destroyed. As a consequence, PK-resistant PrP (referred to as 
PrP Sc ) can be used as a biochemical marker for the presence of 
prions. 8 Unfortunately, the treatment of histological sections 
with PK destroys the tissue microarchitecture. Therefore, on 
histological sections we refer to these abnormal disease-specific 
PrP accumulations as PrP d . However, to confirm the pres-
ence of PrP Sc , adjacent sections were applied to nitrocellulose 
membrane, treated with PK, and subsequently analyzed by 
paraffin-embedded tissue (PET) immunoblot analysis. 29 
 Figure 1   Receptor activator of NF-  B ligand (RANKL) neutralization depletes glycoprotein 2 (GP2   +   ) microfold cells (M cells) within the follicle-
associated epithelium (FAE) of Peyer ’ s patches. Whole-mount immunohistochemical analysis of the effect of anti-RANKL monoclonal antibody (mAb) 
treatment on the presence of GP2   +   M cells within the FAE of Peyer ’ s patches. ( a ) Tissues were stained with GP2-specific mAb (green), the lectin UEA-
1 (red), and phalloidin (blue) to detect F-actin. The positions of the X – Z and Y – Z projections of the FAE are indicated by the solid line in the X – Y image. 
Arrows indicate GP2   +   M cells with characteristic basolateral pockets. Arrowheads indicate GP2   −   UEA-1   +   goblet cells. The boxed areas in each of the 
main panels are shown on the right-hand side at higher magnification with their X – Z and Y – Z projections. Scale bars: main panels, 100   m; boxed 
areas, 25   m. ( b ) The number of M cells in the FAE was significantly reduced after anti-RANKL mAb treatment ( P  =  0.0079). Data are representative 
of 3 – 5 Peyer ’ s patches from each of four control and four anti-RANKL mAb-treated mice. 
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We have repeatedly shown in a series of studies that these PrP d /
 PrP Sc accumulations occur only in prion-infected tissues, and cor-
relate closely with the presence of ME7 scrapie prions. 1,3,10,23 
 In Peyer ’ s patches from control mice, heavy PrP d accumu-
lations, consistent with localization upon FDC within B-cell 
follicles, were detected at 15 weeks after oral prion exposure 
( Figure 3a ). PET immunoblot of adjacent histological sections 
confirmed the presence of high levels of PrP Sc upon FDC in 
tissues from control mice ( Figure 3b ). At the terminal stage of 
disease, high levels of PrP Sc were maintained upon FDC in the 
Peyer ’ s patches, MLNs, and spleens of control Ig-treated mice 
( Figure 3c ). In contrast, in the absence of M cells at the time of 
 Figure 2   Receptor activator of NF-  B ligand (RANKL) neutralization does not affect the status of follicular dendritic cells (FDC) or mononuclear 
phagocytes within the gut-associated lymphoid tissue (GALT) and spleen. ( a ) Immunohistochemical (IHC) analysis of the CD21 / CD35-expressing 
FDC networks (red) within B-cell follicles (B220   +   cells, green) in the GALT and spleens of anti-RANKL monoclonal antibody (mAb)-treated and 
control mice suggested no observable effect of treatment on FDC status. ( b ) No observable effect of RANKL neutralization on cellular prion protein 
(PrP C ) expression (green) by FDC (CD35   +   cells; red) was detected by IHC. ( c ) No observable effect of RANKL neutralization on the status of F4 / 80   +   
macrophages and CD11c   +   cells in the intestine, GALT, and spleen. Dotted line (upper right panels) indicates luminal surface of follicle-associated 
epithelium. Boxed areas are displayed at higher power in underlying panels. Data are representative of tissues from four mice per group. Scale 
bars  =  50   m unless stated otherwise. MLNs, mesenteric lymph nodes. 
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prion exposure, PrP Sc accumulation within the GALT and spleen 
was blocked. No PrP Sc was observed upon FDC in the Peyer ’ s 
patches, MLNs, or spleens from anti-RANKL mAb-treated mice 
collected at 15 weeks after exposure ( Figures 3a and b ), or at 454 
days after exposure at which time the experiment was stopped 
( Figure 3c ). These data clearly demonstrate that in the absence 
of M cells in the FAE at the time of oral exposure, the uptake of 
prions into Peyer ’ s patches was blocked. 
 M cell-depletion blocks prion neuroinvasion from 
the intestine 
 We next determined the effect of M cell-depletion on prion dis-
ease susceptibility. All control-Ig-treated mice succumbed to clin-
ical prion disease after oral exposure to ME7 scrapie prions with a 
mean incubation period of 341 days ( n  =  8;  Table 1 ). In contrast, 
the depletion of M cells blocked disease susceptibility as all of 
the anti-RANKL mAb-treated mice remained free of the clinical 
signs of prion disease up to at least 454 days after oral exposure at 
which time the experiment was stopped ( n  =  8;  Table 1 ). 
 Characteristic spongiform pathology, astrogliosis, microglio-
sis, and PrP Sc accumulation typically associated with terminal 
infection with ME7 scrapie prions were detected in the brains of 
all clinically affected control-Ig-treated mice ( Figure 4a , upper 
row). The severity and distribution of the spongiform pathology 
within the brains of the clinically affected control mice was like-
wise typical of mice clinically affected with ME7 scrapie prions 
( Figure 4b ). In contrast, none of the histopathological charac-
teristics of prion disease were detected within the brains of any 
of the anti-RANKL mAb-treated mice in which M cells were 
depleted before oral exposure ( Figure 4 , middle row). 
 Figure 3   M cell-depletion blocks prion accumulation in the gut-associated lymphoid tissue (GALT) and spleen. Mice were treated with anti-receptor 
activator of NF-  B ligand (RANKL) monoclonal antibody (mAb) to deplete their microfold cells (M cells) and orally infected with the ME7 scrapie agent. 
Tissues were collected 105 days post infection ( a and  b ,  n  =  4 mice per group) or at the end stage of disease ( b ),  n  =  8 mice per group). ( a ) High levels 
of prion protein (PrP) d (brown, right-hand columns) were detected in association with follicular dendritic cells (FDC) (red, left-hand columns) in the 
B-cell follicles (green, middle columns) of Peyer ’ s patches, mesenteric lymph nodes (MLNs), and spleens of prion-infected control-Ig-treated mice. 
( b and  c ) Analysis of adjacent sections by paraffin-embedded tissue-immunoblot analysis confirmed the presence of proteinase K-resistant PrP Sc 
(blue / black). In contrast, no PrP Sc was detected in any of the Peyer ’ s patches, MLNs, and spleens of anti-RANKL mAb-treated mice, which lacked 
M cells at the time of oral exposure. Arrows indicate ( a ) PrP d and ( b ) PrP Sc accumulation upon the same FDC networks.  a , scale bar  =  100   m.  c , scale 
bar  =  200   m. Clinical observation: presence of clinical signs of prion disease at the time of cull. dpi, days post oral prion infection. 
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 DISCUSSION 
 These data suggest that M cells are important sites of prion 
uptake from the gut lumen into Peyer ’ s patches after oral expo-
sure. In order to study the role of M cells in oral prion patho-
genesis, a mouse model was used in which M cells within the 
FAE of Peyer ’ s patches could be depleted through treatment 
with anti-RANKL mAb. Our data show that coincident with 
the depletion of M cells by RANKL neutralization, the early 
accumulation of prions upon FDC in the GALT and spleen 
was blocked. Furthermore, we show that in the absence of 
M cells at the time of oral exposure, the spread of prions from 
the intestinal lumen to the brain and disease susceptibility were 
also blocked. Although a number of mechanisms have been sug-
gested through which prions may cross the intestinal epithelium 
after oral exposure, these data suggest that M cells are the main 
sites of uptake. 
 The translocation of PrP d across the intestinal epithelium 
in sheep has been studied in an  in vivo gut loop model. 19 In 
these studies, scrapie-affected brain homogenate was injected 
directly into the ligated gut lumen and the dissemination of 
the inoculum monitored by IHC. In contrast to the data in the 
current study, these studies suggested that prion uptake across 
the gut epithelium occurred via enterocytes independently of 
M cell-mediated transcytosis. However, if enterocytes do signifi-
cantly contribute to the translocation of prions across the gut 
epithelium  in vivo , one would not expect the specific depletion 
of M cells to completely block oral prion disease susceptibility 
as shown here. The reasons for the discrepancies between these 
studies are uncertain. In the sheep studies, no intra-epithelial 
cell-associated PrP d was detected suggesting that the prions may 
have been carried into the Peyer ’ s patches by M cells at levels 
below the threshold of IHC detection. In addition, large quanti-
ties of prion-infected brain homogenate were injected directly 
into the lumen of the ligated gut loops. This may have protected 
the prions from any possible degradative effects of digestive 
enzymes as they travel along the gastrointestinal tract after oral 
exposure. As a consequence, the presence of much higher dose 
of prions may have facilitated their uptake into an alternative 
compartment to that utilized following exposure to physiologi-
cally relevant doses via the oral cavity. To avoid these issues in 
the current study, we deliberately chose to infect the mice by 
ingestion of prion-contaminated food pellets to closely model 
oral pathogenesis via a physiologically relevant and natural route 
of exposure. Of course, although a role for RANK stimulation 
in antigen uptake by enterocytes has not been described, data 
in the current study cannot entirely exclude the possibility that 
RANKL neutralization may have affected the uptake of prions 
by these cells. 
 The mechanism through which prions may be acquired by 
M cells is uncertain. The identification of the molecules involved 
may reveal important targets for the design of treatments to 
specifically block the uptake of prions from the gut lumen. Prion 
uptake into M cells could occur nonspecifically, via pinocytosis, 
or specifically via receptor-mediated endocytosis. For exam-
ple, the glycoprotein GP2 on the apical plasma membrane of 
M cells acts as a transcytotic receptor for mucosal antigens. 25 
The demonstration that M cells express high levels of PrP C on 
their surfaces highlights another plausible molecular mecha-
nism by which prions 14 and other pathogenic microorganisms 30 
may be specifically acquired. Tunneling nanotubes have been 
proposed as an intercellular conduit through which prions may 
disseminate between cells. 31 The protein M-Sec (encoded by 
 Tnfaip2 ) is expressed at high levels by M cells and mono nuclear 
phagocytes, and functions as a key regulator of tunneling nano-
tubes formation. 32 Most M cells within the FAE of Peyer ’ s 
patches appear to have a one-to-one association with mono-
nuclear phagocytes, which extend their dendritic processes 
into the basolateral pockets of M cells. 33 This tight association 
raises the suggestion that prions may also be transferred between 
M cells and mononuclear phagocytes via tunneling nanotubes. 
 Although RANK – RANKL stimulation is important for 
the development and function of M cells, 13 osteoclasts, 27 and 
lymphoid tissue inducer cells, 34 our data show that RANKL 
neutralization did not appear to affect the status of FDC and 
mononuclear phagocytes in the GALT. These data are consist-
ent with the restriction of high levels of RANK expression to 
the epithelium in the intestine 13 and expression of negligible 
levels of  Tnfrsf11a by Peyer ’ s patch lymphocytes, 35 FDC, macro-
phages, and classical DC (including Peyer ’ s patch classical DC) 
when compared with the FAE, osteoclasts, and lymphoid tissue 
inducer cells ( Supplementary Figure 1 online). Previous studies 
have suggested that RANKL can promote the survival of bone 
marrow-derived DC and their expression of pro-inflammatory 
cytokines such as IL-12 p40. 36,37 However, these data were 
derived from the  in vitro analysis of bone marrow-derived DC, 
which have a distinct transcriptomic profile from tissue classical 
 Table 1  Effect of M cell-depletion on susceptibility to oral prion infection 
 Treatment  a  
 Disease incubation 
periods or survival 
times (days)  b  
 Mean disease 
incubation period 
(days ± SEM) 
 Clinical 
disease  c  
 Vacuolar pathology 
in brain  PrP  Sc   in brain 
 PrP  Sc   in GALT 
and spleen 
 Control Ig  307, 314, 328, 328, 
328, 349, 349, 426 
 341 ± 13  8 / 8  8 / 8  8 / 8  8 / 8 
       
 Anti-RANKL mAb  8X   >   454   0 / 8  0 / 8  0 / 8  0 / 8 
 Abbreviations: GALT, gut-associated lymphoid tissue; mAb, monoclonal antibody; PrP, prion protein; RANKL, receptor activator of NF-  B ligand. 
 a Mice were treated with anti-RANKL mAb for 8 days (or control Ig) and 2 days later orally infected with ME7 scrapie prions. 
 b The notation  “ NX   >   454 ” means mice that were free of the clinical and histopathological signs of prion disease up to at least this time after oral exposure. 
 c Incidence=number of animals affected / number of animals tested. 
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DC. 38 Indeed, unlike bone marrow-derived DC, mucosal 
DC from Peyer ’ s patches and MLNs express very low levels of 
RANK on their surfaces and do not exhibit prolonged survival 
or induce IL-12 p40 expression in response to RANKL treat-
ment. 39 Furthermore, the density and distribution of CD11c   +  
cells is also unaffected in cryptopatches of RANKL   −  /  −   mice. 28 
Thus, while a potential role for RANK – RANKL stimulation in 
antigen uptake from the gut lumen cannot be entirely excluded, 
these data suggest that possible effects of RANKL neutralization 
on DC were not the major influence on oral prion pathogenesis. 
Although an important role for RANK – RANKL stimulation 
in the regulation of bone remodeling by osteoclasts has been 
described, 27 a temporary blockade of this activity after treat-
ment with anti-RANKL mAb is highly unlikely to influence the 
early uptake of prions into Peyer ’ s patches. Taken together, these 
data, and data from the current study, suggest the major effect 
of RANKL neutralization on oral prion susceptibility was due 
to effects on M cell-differentiation. 
 Figure 4   M cell-depletion blocks prion disease susceptibility after oral exposure. Control (control Ig) and M cell-depleted anti-receptor activator of 
NF-  B ligand (RANKL) monoclonal antibody (mAb)-treated mice were orally infected with ME7 scrapie prions. Brains were collected from clinically 
scrapie-affected mice and mice that were free of the clinical signs of prion disease at the end of the experiment (454 days after exposure), and the 
neuropathology within each brain was compared. ( a ) High levels of spongiform pathology (hematoxylin and eosin (H & E), left-hand column), heavy 
accumulations of disease-specific prion protein (PrP) (brown, middle column), reactive astrocytes expressing glial fibrillary acidic protein (GFAP) 
(brown, fourth column), and active microglia expressing Iba-1 (brown, right-hand column) were detected in the brains of all clinically scrapie-affected 
control mice (upper row). Analysis of adjacent sections by paraffin-embedded tissue-immunoblot analysis confirmed the presence of proteinase K-
resistant PrP Sc (blue / black, second column). In contrast, none of the M cell-depleted anti-RANKL mAb-treated mice (middle row) developed clinical 
signs of prion disease during their life spans or displayed histopathological signs of prion disease in their brains. Data are representative of tissues from 
eight mice per group. ( b ) Pathological assessment of the spongiform change (vacuolation) in brains from terminally scrapie-affected mice and mice 
that remained free of the signs of disease at the end of the experiment. Vacuolation was scored on a scale of 0 – 5 in the following gray (G1 – G9) and 
white (W1 – W3) matter areas: G1, dorsal medulla; G2, cerebellar cortex; G3, superior colliculus; G4, hypothalamus; G5, thalamus; G6, hippocampus; 
G7, septum; G8, retrosplenial and adjacent motor cortex; G9, cingulate and adjacent motor cortex; W1, inferior and middle cerebellar peduncles; 
W2, decussation of superior cerebellar peduncles; and W3, cerebellar peduncles. Data are representative of tissues from eight mice per group. 
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 Data from the current study and elsewhere suggest that after 
oral exposure, prion neuroinvasion occurs by the following cel-
lular relay. After ingestion of a contaminated meal, prions are 
initially transcytosed across the FAE from the intestinal lumen 
by M cells. In the absence of M cells, the intestinal epithelium 
appears to act an impermeable barrier to the uptake of prions, 
and as a consequence the prions are most likely degraded within 
the gut lumen and excreted. Once the prions have crossed the 
epithelium, they are subsequently acquired by mononuclear 
phagocytes, which appear to act as  ‘ Trojan horses ’ and carry 
them towards the B-cell follicles within the Peyer ’ s patches. 23 
The prions are then acquired by FDC, which are considered to 
amplify the prions above the threshold level required for neu-
roinvasion. 1,3,7 Following their expansion upon FDC, prions 
subsequently infect neighboring nerve fibers of the enteric nerv-
ous system. Prions are mainly considered to spread to the central 
nervous system via the peripheral nervous system, 12 (sympa-
thetic and parasympathetic), although the hematogenous route 
may provide a parallel pathway of neuroinvasion. 
 Diet (consumption of prion-contaminated food) and prion 
protein genotype are important factors that affect prion disease 
susceptibility. The status of lymphoid tissue architecture in the 
gut also has a role as inflammation may enhance prion uptake 
or expand their tissue distribution 3,40,41 demonstrated by the 
fact that bacterial colitis alters oral prion susceptibility. 42 The 
effects of intestinal inflammatory responses on M cell density 
may also influence prion pathogenesis. For example, recom-
binant-RANKL treatment stimulates the widespread expan-
sion of functional M cells enhancing the uptake of antigens and 
enteric bacteria, 13 and M cell status can also be influenced by the 
presence of pathogenic bacteria in the gut lumen. 43,44 These data 
suggest it is plausible that the triggering of M cell-differentiation 
by concurrent infection with an intestinal pathogen or inflam-
matory stimuli may also influence oral prion susceptibility. 
 In conclusion, our data suggest that M cells are important sites 
of prion uptake from the gut lumen into Peyer ’ s patches. In the 
absence of M cells at the time of oral exposure, prion accumula-
tion upon FDC in the GALT, neuroinvasion, and disease suscep-
tibility are blocked. Antigen uptake by M cells is an important 
initial step in the induction of efficient immune responses after 
oral vaccination. Furthermore, the targeted delivery of vaccine 
antigens to M cells is an effective means of inducing antigen-
specific immune responses. 45 Mucosal immunization has been 
shown to have significant efficacy against oral prion infection in 
mice. 46 Therefore, data in the current study suggest M cells rep-
resent a novel cellular target for intervention in orally acquired 
prion infections. 
 METHODS 
 Mice .  C57BL / 6 mice (6 – 8 weeks old) were used throughout this study. 
Mice were maintained under specific pathogen free (SPF) conditions. 
All studies using experimental mice and regulatory licenses were 
approved by both The Roslin Institute ’ s and University of Edinburgh ’ s 
Protocols and Ethics Committees. All animal experiments were carried 
out under the authority of a UK Home Office Project Licence within the 
terms and conditions of the strict regulations of the UK Home Office 
 ‘Animals (scientific procedures) Act 1986 ’. Where necessary, anesthesia 
appropriate for the procedure was administered, and all efforts were 
made to minimize harm and suffering. Mice were humanely culled 
using a UK Home Office Schedule One method. 
 Treatment with anti-RANKL mAb .  To neutralize the activity of 
RANKL  in vivo , mice were injected intraperitoneally with 250   g of 
the IK22-5 rat anti-mouse RANKL mAb 47 every 2 days for 8 days as 
described. 13 A parallel group of mice were treated with an isotype-
matched nonspecific rat mAb, rat IgG2a   (eBioscience, San Diego, 
CA) as a control. 
 Prion exposure and disease monitoring .  For oral exposure, mice were 
fed individual food pellets doused with 50   l of a 10 % (w / v) dilution of 
scrapie brain homogenate prepared from mice terminally affected with 
ME7 scrapie prions (containing  ~ 2.5 × 10 4 intra-cerebral ID 50 units). 
To do so, during the dosing period mice were individually housed in 
bedding- and food-free cages. Water was provided  ad libitum . A single 
prion-dosed food pellet was then placed in the cage. The mice were 
returned to their original cages (with bedding and food  ad libitum ) as 
soon as the food pellet was observed to have been completely ingested. 
The use of bedding-free and additional food-free cages ensured easy 
monitoring of consumption of the prion-contaminated food pellet. 
Following exposure, mice were coded and assessed blindly for the signs 
of clinical prion disease and culled at a standard clinical endpoint. 48 
Survival times were recorded for mice that did not develop clinical 
signs of disease. Scrapie diagnosis was confirmed blindly on coded 
sections by histopathological assessment of vacuolation in the brain. 
For the construction of lesion profiles, vacuolar changes were scored in 
nine gray-matter and three white-matter areas of brain as described. 49 
Where indicated, some mice were culled at the times indicated post 
injection with prions and tissues taken for further analysis. 
 IHC and immunofluorescent analyses.  For whole-mount staining, 
Peyer ’ s patches were dissected from small intestines and fixed with 
BD Cytofix / Cytoperm (BD Biosciences, Oxford, UK). Tissues were 
subsequently immunostained with rat anti-mouse GP2 mAb (MBL 
International, Woburn, MA). Following addition of primary Ab, tis-
sues were stained with Alexa Fluor 488-conjugated anti-rat IgG Ab 
(Invitrogen, Paisley, UK), rhodamine-conjugated  Ulex europaeus agglu-
tinin I (UEA-1; Vector Laboratories, Burlingame, CA), and Alexa Fluor 
647-conjugated phalloidin (Invitrogen). 
 Intestines, MLNs, and spleens were removed and snap-frozen at the 
temperature of liquid nitrogen. Serial frozen sections (10   m in thickness) 
were cut on a cryostat and immunostained with the following anti bodies: 
FDC were visualized by staining with mAb 7G6 to detect CR2 / CR1 
(CD21 / CD35) and mAb 8C12 to detect CR1 (CD35; BD Biosciences). 
Cellular PrP C was detected using PrP-specific polyclonal antibody (pAb) 
1B3. 50 B cells were detected using rat anti-mouse B220 mAb (clone RA3-
RB2, Caltag, Towcester, UK). Mononuclear phagocytes were detected 
using rat anti-mouse F4 / 80 mAb (clone CI:A31, AbD serotec, Kidlington, 
UK) and hamster anti-mouse CD11c mAb (clone N418, AbD Serotec). 
 For the detection of disease-specific PrP (PrP d ) in Peyer ’ s patches, 
MLNs, spleens, and brains, tissues were fixed in periodate-lysine-
paraformaldehyde fixative and embedded in paraffin wax. Sections 
(thickness 6   m) were deparaffinized, and pre-treated to enhance the 
detection of PrP d by hydrated autoclaving (15  min, 121 ° C, hydration) 
and subsequent immersion formic acid (98 % ) for 5  min. Sections were 
then immunostained with 1B3 PrP-specific pAb. For the detection of 
astrocytes, brain sections were immunostained with anti-glial fibrillary 
acidic protein (GFAP; DAKO, Ely, UK). For the detection of microglia, 
deparaffinized brain sections were first pre-treated with Target Retrieval 
Solution (DAKO) and subsequently immunostained with anti-ionized 
calcium-binding adaptor molecule 1 (Iba-1; Wako Chemicals GmbH, 
Neuss, Germany). Immunolabelling was revealed using HRP-conju-
gated to the avidin – biotin complex (Novared kit, Vector Laboratories, 
Peterborough, UK). PET immunoblot analysis was used to confirm 
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the PrP d detected by immunohistochemistry, which was PK-resistant 
PrP Sc . 29 Membranes were subsequently immunostained with 1B3 PrP-
specific pAb. 
 For light microscopy, following the addition of primary antibodies, 
biotin-conjugated species-specific secondary antibodies (Stratech, 
Soham, UK) were applied and immunolabelling was revealed using 
HRP-conjugated to the avidin – biotin complex. Sections were coun-
terstained with hematoxylin to distinguish cell nuclei. For fluorescent 
microscopy, following the addition of primary antibody, streptavidin-
conjugated or species-specific secondary antibodies coupled to Alexa 
Fluor 488 (green), Alexa Fluor 594 (red), or Alexa Fluor 647 (blue) dyes 
(Invitrogen) were used. Sections were mounted in fluorescent mount-
ing medium (DAKO) and examined using a Zeiss LSM5 confocal 
microscope (Zeiss, Welwyn Garden City, UK). 
 Statistical analyses .  Data are presented as mean ± s.e. Unless indicated 
otherwise, significant differences between samples in different groups 
were sought by Student ’ s t-test. Values of  P  <  0.05 were accepted as 
significant. 
 SUPPLEMENTARY MATERIAL is linked to the online version of the 
paper at  http://www.nature.com/mi 
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